1. Home
  2. SRTS vs GANX Comparison

SRTS vs GANX Comparison

Compare SRTS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sensus Healthcare Inc.

SRTS

Sensus Healthcare Inc.

HOLD

Current Price

$4.45

Market Cap

65.5M

Sector

Health Care

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.82

Market Cap

72.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRTS
GANX
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.5M
72.7M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
SRTS
GANX
Price
$4.45
$1.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$6.67
$7.50
AVG Volume (30 Days)
38.2K
712.5K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.46
EPS
N/A
N/A
Revenue
$27,482,000.00
$55,180.00
Revenue This Year
$2.00
N/A
Revenue Next Year
$34.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.03
$1.41
52 Week High
$5.92
$4.34

Technical Indicators

Market Signals
Indicator
SRTS
GANX
Relative Strength Index (RSI) 58.74 39.30
Support Level $3.66 $1.55
Resistance Level $4.80 $2.03
Average True Range (ATR) 0.27 0.15
MACD 0.07 -0.02
Stochastic Oscillator 87.34 27.03

Price Performance

Historical Comparison
SRTS
GANX

About SRTS Sensus Healthcare Inc.

Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: